Clinical Trial Update: Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients

View source ↗

Summary

Expanded Access program for AVM0703 is available to eligible patients with several solid tumor and blood cancer indications, including glioblastoma and squamous…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Gastric Cancer
• Glioblastoma
• Hodgkin Lymphoma
• Non-hodgkin Lymphoma
• Ovarian Cancer
• Prostate Cancer
• Squamous Cell Carcinoma

Drugs mentioned

• AVM0703

Snippet

Sponsor: AVM Biotechnology Inc | Conditions: Glioblastoma, Squamous Cell Carcinoma | Status: AVAILABLE